BofA Securities, Research Division Chi Meng Fong Presentation Okay. Great. Maybe start with some high-level questions, if we may, before we dive into some of the deeper product level questions. Good morning, everyone. Thanks for joining the BofA Healthcare Conferences. My name is Chi Fong, I have [ Dina Ramadane ] with me today, we are both from the U.S. Bio-pharmaceutical Health Care Team here, Bank of America. I cover Roivant, she covers Immunovant. We are glad to be co-hosting CEO of Roivant, Matthew Gli ...

Roivant Sciences (NasdaqGS:ROIV) 2026 Conference May 13, 2026 01:00 PM ET Speaker2 Let's get started. Good morning, everyone. Thanks for joining the BofA Healthcare Conferences. My name is Qi Fang. I have Madina Ramadhan with me today. We are both from the U.S. Biopharmaceutical Healthcare team here at Bank of America. I cover Roivant, she covers Immunovant, and we are glad to be co-hosting CEO of Roivant, Matt Gline, today. Thanks for joining us, Matt. Speaker1 I'm so happy to be here. Thank you. Speaker2 ...

公司业务与战略 - Roivant是一家生物制药公司，其使命是通过加速重要药物的开发和商业化来改善患者生活[3] - 公司通过创建灵活的子公司或“Vants”来推进其产品管线，以开发和商业化其药物与技术[3] - 除了治疗领域，公司还孵化发现阶段的公司和与其生物制药业务互补的健康科技初创公司[3] 产品研发管线 - 公司管线包括brepocitinib，这是一种强效的JAK1和TYK2小分子抑制剂，正在开发用于治疗皮肌炎、非感染性葡萄膜炎、皮肤结节病和扁平苔藓[3] - 管线还包括IMVT-1402和batoclimab，这两种是完全人源化抗FcRn单克隆抗体，正在针对多种IgG介导的自身免疫适应症进行开发[3] - 管线中还有mosliciguat，这是一种吸入式sGC激活剂，正在开发用于治疗与间质性肺病相关的肺动脉高压[3] 公司近期动态 - 公司将于2026年5月20日美国东部时间上午8:00举行电话会议和网络直播，报告其截至2026年3月31日的第四季度及整个财年的财务业绩，并提供业务更新[1] - 电话会议的接入信息和网络直播详情可在公司官网投资者关系板块的“活动与演示”部分获取，直播录像也将在会议结束后于官网提供[2]